NASDAQ:ALPN • US02083G1004
Past quarterly earnings results for ALPINE IMMUNE SCIENCES INC (ALPN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2024 | -0.28 | -0.42 | 33.62% | - | 7.032M | 3.586M | 96.10% | -25.09% |
| Q4 2023 | 0.12 | -0.34 | 135.04% | 129.27% | 30.853M | 9.286M | 232.25% | 1,009.82% |
| Q3 2023 | -0.24 | -0.34 | 29.64% | 42.86% | 10.043M | 7.394M | 35.83% | 19.99% |
| Q2 2023 | -0.27 | -0.38 | 29.29% | 55.00% | 8.593M | 9.027M | -4.81% | 62.44% |
| Q1 2023 | -0.28 | -0.38 | 25.93% | -12.00% | 9.387M | 8.772M | 7.01% | -31.13% |
| Q4 2022 | -0.41 | -0.27 | -49.99% | 21.15% | 2.78M | 11.184M | -75.14% | -38.63% |
| Q3 2022 | -0.42 | -0.10 | -301.72% | 23.64% | 8.37M | 19.059M | -56.08% | -1.76% |
| Q2 2022 | -0.60 | -0.40 | -49.87% | -30.43% | 5.29M | 10.245M | -48.37% | -26.43% |
| Q1 2022 | -0.25 | -0.19 | -30.72% | 44.44% | 13.63M | 16.589M | -17.84% | 325.94% |
| Q4 2021 | -0.52 | -0.31 | -67.15% | -92.59% | 4.53M | 14.249M | -68.21% | -19.68% |
| Q3 2021 | -0.55 | 0.01 | -10,884.31% | -96.43% | 8.52M | 21.611M | -60.58% | 346.07% |
| Q2 2021 | -0.46 | -0.40 | -13.88% | 13.21% | 7.19M | 6.606M | 8.84% | 942.03% |
| Q1 2021 | -0.45 | -0.36 | -23.69% | -50.00% | 3.2M | 5.671M | -43.57% | 193.58% |
| Q4 2020 | -0.27 | -0.32 | 15.07% | - | 5.64M | 2.639M | 113.72% | - |
| Q3 2020 | -0.28 | -0.24 | -18.07% | - | 1.91M | 16.399M | -88.35% | - |
| Q2 2020 | -0.53 | 0.55 | -197.12% | - | 690K | 16.93M | -95.92% | - |
| Q1 2020 | -0.30 | -0.48 | 37.42% | - | 1.09M | 384.203K | 183.70% | - |
Notes
ALPINE IMMUNE SCIENCES INC (ALPN) last reported earnings on 5/9/2024.
ALPINE IMMUNE SCIENCES INC (ALPN) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, ALPINE IMMUNE SCIENCES INC (ALPN) has beaten EPS estimates in 4 out of 4 releases.